Scott Brun, Ph.D.

Scott received his BS degree in Biochemistry from the University of Illinois, Urbana-Champaign, and subsequently earned an MD degree from the Johns Hopkins University School of Medicine. He completed his residency in ophthalmology at the Massachusetts Eye and Ear Infirmary/Harvard Medical School.

In 1997, Scott joined Abbott Laboratories, where he held positions of increasing leadership responsibility in drug development within the R&D organization. When AbbVie launched as an independent biopharmaceutical company in 2013, Scott was named Vice President and Head of Pharmaceutical Development. Scott oversaw a global organization with responsibilities for AbbVie’s entire portfolio of early and late stage clinical preregistration pipeline compounds as well as marketed compounds within oncology, neurology, immunology, renal, infectious disease, and women’s and men’s health therapeutic areas. A variety of phase 2 and 3 programs initiated and executed during his tenure resulted in multiple therapies being introduced to the clinic,  including Mavyret (leading global curative therapy for HCV infection), Venclexta (first in class BCL-2 inhibitor for hematologic malignancies), Orilissa (first in class GnRH antagonist for endometriosis), and Rinvoq (selective JAK-1 inhibitor for rheumatoid arthritis).

Most recently, Scott was Vice President of Scientific Affairs and Head of AbbVie Ventures, a corporate venture fund responsible for investment opportunities within the company’s current R&D therapeutic areas as well as technology platforms of interest. Under Scott’s leadership, the group expanded its investment portfolio to include over 20 active companies, leading to Abbvie Ventures being identified as one of the top most active corporate and institutional new venture investors. Along with the Chief Scientific Officer, Scott served as AbbVie’s primary spokesperson for R&D to global media, governmental officials, and investors.

Scott retired from AbbVie in 2019 to pursue family and personal interests and is currently serving in several board, consulting, and advisory positions within the academic, VC, and biopharmaceutical industry communities.